1. Introduction {#sec1-cancers-11-01239}
===============

Together with the aging of the population in Western countries, the number of older people with cancer has increased considerably in the last decade \[[@B1-cancers-11-01239]\]. In the Netherlands, breast cancer (BC) is the most common cancer in women, with an estimated incidence rate of 66 new cases per 100,000 women \[[@B2-cancers-11-01239]\]. The incidence of BC is highest in patients aged 70--74 years (212 per 100,000 women) \[[@B2-cancers-11-01239]\]. One of the most common cancers in both men and women is colorectal cancer (CRC), with an estimated incidence of 65 new cases per 100,000 persons. Its incidence increases with age (415 per 100,000 per persons in those aged 75--79 years) \[[@B2-cancers-11-01239]\].

Though the group of older patients has increased considerably, evidence to guide treatment of these patients remains limited \[[@B3-cancers-11-01239]\]. Many clinical trials exclude older patients from participating \[[@B4-cancers-11-01239]\], and older patients who do participate in clinical trials may not be representative of the general older population, as clinical trials often exclude older patients with comorbidities or poor overall health \[[@B5-cancers-11-01239]\].

Several population-based studies showed that the survival rate of BC patients has improved substantially in the last two decades \[[@B1-cancers-11-01239],[@B6-cancers-11-01239],[@B7-cancers-11-01239],[@B8-cancers-11-01239]\]. This has been attributed particularly to mammographic screening programs \[[@B9-cancers-11-01239]\] and advances in treatment (e.g., improved radiotherapy techniques and new systemic therapeutic agents such as third-generation chemotherapy, aromatase inhibitors, and HER2-targeted therapies). Clinical guidelines, as well as international position papers, state that surgery is recommended for early-stage BC patients \[[@B3-cancers-11-01239],[@B10-cancers-11-01239]\]. Adjuvant chemotherapy is recommended for node-positive or high-risk node-negative disease, and endocrine therapy is recommended for high-risk receptor-positive disease \[[@B3-cancers-11-01239],[@B10-cancers-11-01239]\]. However, population-based studies showed that older BC patients are less likely to receive standard care, which has been linked to lower survival rates in older patients \[[@B6-cancers-11-01239],[@B8-cancers-11-01239],[@B11-cancers-11-01239]\].

Surgery is recommended in early-stage CRC patients. To reduce the risk of recurrence after surgery, clinical guidelines recommend that all lymph node-positive patients should be considered for adjuvant treatment, e.g., radiotherapy, or chemotherapy \[[@B12-cancers-11-01239],[@B13-cancers-11-01239]\]. Several population-based studies showed that the administration of adjuvant chemotherapy has increased considerably in recent years, and that this is associated with improved survival \[[@B14-cancers-11-01239],[@B15-cancers-11-01239]\]. However, the administration of adjuvant chemotherapy is considerably less common in older patients \[[@B14-cancers-11-01239]\].

Several studies state that age should not be a contraindication for surgery or adjuvant chemotherapy \[[@B16-cancers-11-01239]\]. Trends in survival and treatment have been published before, but this has not clarified the differences in survival rates between cancers. The aim of this study was to investigate trends in survival rates and treatment patterns over time for older versus younger patients with BC and CRC in the Netherlands.

2. Results {#sec2-cancers-11-01239}
==========

Between 2003 and 2012, 127,146 patients were diagnosed with stages I--III BC in the Netherlands, while 85,629 patients were diagnosed with stages I--III CRC ([Table 1](#cancers-11-01239-t001){ref-type="table"}). The median age of patients with BC was 60 years (range 18 to 103), and the median age of patients with CRC was 71 years (range 18 to 102).

2.1. Stage at Diagnosis
-----------------------

The stages at diagnosis according to age are presented in [Figure 1](#cancers-11-01239-f001){ref-type="fig"}. BC patients aged ≤45 or ≥75 years were more often diagnosed with stage II or III cancer compared to those aged 45--75 years (*p* \< 0.001). Stage II was diagnosed in 51.7% and stage III in 17.9% of the BC patients aged ≥75 years. The percentage of CRC patients with stage II disease steadily increased with age (32.5% in CRC patients aged 45--54 years, and 44.3% in CRC patients aged ≥75 years), while stage III decreased with age (46.7% in CRC patients aged 45--54 years, and 33.3% in CRC patients aged ≥75 years, *p* \< 0.001).

2.2. Trends in Treatment {#sec2dot2-cancers-11-01239}
------------------------

The time trends for all treatments for BC patients between 2003 and 2012 are presented in [Figure 2](#cancers-11-01239-f002){ref-type="fig"}. Over the entire study period, 98.0% of patients with stages I--III BC who were younger than 75 years underwent surgery, whereas for those aged 75 years or over, surgery rates declined from 79.3% in 2003 to 66.7% in 2012 (*p* \< 0.001, [Figure 2](#cancers-11-01239-f002){ref-type="fig"}a). The proportion of BC patients undergoing lymph node dissection for node-positive disease decreased over time for all age groups ([Figure 2](#cancers-11-01239-f002){ref-type="fig"}b). The use of radiotherapy after breast-conserving surgery increased significantly for all age groups but was lowest among patients aged 75 years and older (73.6% in 2003 vs. 84.1% in 2012, *p* \< 0.001) and highest among patients aged 45--54 years (84.4% in 2003 vs. 96.2% in 2012, *p* \< 0.001, [Figure 2](#cancers-11-01239-f002){ref-type="fig"}c). Primary endocrine therapy as a monotherapy in BC patients was almost exclusively used for patients aged 75 years or over, and increased significantly over time (16.5% in 2003 and 28.7% in 2012, *p* \< 0.001, [Figure 2](#cancers-11-01239-f002){ref-type="fig"}d). The use of adjuvant chemotherapy in stages II and I BC patients increased significantly over time for all age groups, except for patients aged 75 years or older. Its use was associated with age, with more than 90% of patients younger than 55 years and less than 9% of patients aged 65 years or older in 2012 receiving it, and hardly any patients aged 75 years or older ([Figure 2](#cancers-11-01239-f002){ref-type="fig"}e,f).

As CRC patients are treated according to tumor location, i.e., colon cancer (CC) or rectal cancer (RC), we report the treatments received for CC and RC separately ([Figure 3](#cancers-11-01239-f003){ref-type="fig"}). In CC, the number of patients aged 75 years or older who underwent surgery declined significantly over time (98.1% in 2003 vs. 94.2% in 2012, *p* \< 0.001, [Figure 3](#cancers-11-01239-f003){ref-type="fig"}a). The percentage of chemotherapy treatment in stage III CC patients aged 55 years or older increased significantly over time ([Figure 3](#cancers-11-01239-f003){ref-type="fig"}b), although the percentage of those aged 75 years or older who received chemotherapy remained considerably lower (16.3% in 2003 vs. 23.5% in 2012, *p* \< 0.001). The percentage of RC patients aged 45 years or older who underwent surgery declined significantly over time, the greatest decrease being observed in RC patients aged 75 years or older (from 91.8% in 2003 to 81.1% in 2012, *p* \< 0.001) ([Figure 3](#cancers-11-01239-f003){ref-type="fig"}c). The use of radiotherapy in stage III RC increased significantly over time for all age groups but became less frequent with increasing age (91.8% of patients aged 55--64 years compared to 80.2% of patients aged 75 years or older in 2012, [Figure 3](#cancers-11-01239-f003){ref-type="fig"}d). The number of RC patients aged 75 years or older undergoing surgery was lower than that of younger patients. The percentage of I-III RC patients aged 75 years or older who received primary radiotherapy as a single treatment modality increased significantly, from 3.8% in 2003 to 9.4% in 2013 (*p* \< 0.001, [Figure 3](#cancers-11-01239-f003){ref-type="fig"}e). The use of chemoradiation in stage II RC patients increased significantly in all age groups, ranging from 19.8% to 71.6% in 2012, but again this was highly dependent on age, with the lowest use in the age group of 75 years and older ([Figure 3](#cancers-11-01239-f003){ref-type="fig"}f).

2.3. Trends in Survival {#sec2dot3-cancers-11-01239}
-----------------------

The 5-year overall survival of BC patients is presented in [Figure 4](#cancers-11-01239-f004){ref-type="fig"}. The 5-year overall survival improved in BC patients (adjusted hazard ratio (HR) 0.78, 95% CI 0.73--0.83) in the period 2003--2012. The 5-year overall survival improved slightly in patients aged 75 years or older (adjusted HR 0.99, 95% CI 0.98--0.99) and did not significantly improve in patients aged 65--74 years (adjusted HR 0.99, 95% CI 0.98--1.01). In the multivariable Cox regression analysis, the overall survival improved in the period 2003--2012 and was influenced significantly by age ([Table 2](#cancers-11-01239-t002){ref-type="table"}). The 5-year relative survival improved in BC patients, from 89.7% in 2003 to 93.1% in 2012 (adjusted relative excess risk (RER) 0.97, 95% CI 0.97--0.98 per year) ([Figure 5](#cancers-11-01239-f005){ref-type="fig"}). The 5-year relative survival rate improved significantly for BC patients aged 65 years or younger over the period between 2003 and 2012. In contrast, the relative survival for BC patients aged 75 years or older did not increase significantly over the same period (crude RER 0.99, 95% CI 0.97--1.02). After adjustment for age, stage, and treatment, the RER for BC patients aged 65--74 years was no longer significant (adjusted RER 1.00, 95% CI 0.98--1.01), and the RER for patients aged 75 years or older remained non-significant (adjusted RER 1.00, 95% CI 0.98--1.01).

Similarly, the 5-year overall survival improved for all CRC patients ([Figure 6](#cancers-11-01239-f006){ref-type="fig"}). Overall survival in CRC patients was influenced by the year of diagnoses and age. Other factors affecting 5-year overall survival were, stage, grade, gender, and treatment. The relative survival for CRC patients improved from 76.0% in 2003 to 80.3% in 2012 (adjusted RER 0.95, 95% CI 0.94--0.95 per year, [Figure 7](#cancers-11-01239-f007){ref-type="fig"}). Most overall improvement was observed in the CRC patients aged 65--74 years. In this group, the 5-year relative survival increased by 7.9% between 2003 and 2012 (adjusted RER 0.94, 95% CI 0.93--0.95). In contrast to the BC cohort, the RERs for patients with CRC in all age groups had improved significantly after adjustment for grade, sex, stage, and treatment (adjusted RERs varying between 0.94 and 0.96 per year).

3. Discussion {#sec3-cancers-11-01239}
=============

The findings of our population-based study show that 5-year overall and relative survival improved for BC patients and for CRC patients in the Netherlands between 2003 and 2012. The difference in 5-year survival between older and younger CRC patients decreased during the study period, and the greatest improvement in overall and relative survival was observed for older CRC patients. Among BC patients, substantial improvement of 5-year relative survival was seen only for younger BC patients. The overall and relative survival and its improvement over time were lower for older BC patients.

Previous population-based studies found that overall and relative survival among older BC patients did not change in the last decade \[[@B17-cancers-11-01239],[@B18-cancers-11-01239]\]. This lack of improvement has been attributed to differences in the delivery of cancer care between older and younger BC patients, e.g., the influence of comorbid conditions on the selection of cancer treatments \[[@B19-cancers-11-01239],[@B20-cancers-11-01239]\]; the lower likelihood of receiving breast surgery, radiotherapy, or adjuvant chemotherapy for older BC patients compared to younger BC patients \[[@B6-cancers-11-01239]\]; and mammographic screening being offered only to younger women \[[@B9-cancers-11-01239]\]. The survival and treatment differences observed in our study suggest possible limitations of cancer treatment, as well as reticence about cancer treatment, for older BC patients.

The most notable finding was the decreasing proportion of older BC patients receiving surgery, and the increasing proportion receiving primary endocrine therapy. Previous population-based studies in the Netherlands confirm this finding \[[@B6-cancers-11-01239],[@B17-cancers-11-01239],[@B21-cancers-11-01239]\]. Van de Glas et al. showed that the proportion of older BC patients that did not receive breast surgery increased substantially from 9.2% in 1995 to 30.1% in 2011 \[[@B17-cancers-11-01239]\]. Moreover, previous population-based studies showed that the proportion of older BC patients receiving primary endocrine therapy is higher in the Netherlands than in other European countries \[[@B22-cancers-11-01239],[@B23-cancers-11-01239],[@B24-cancers-11-01239]\]. The EUROCARE breast cancer group found lower survival rates in European countries, like England and Ireland, where older BC patients are treated more often with primary endocrine therapy omitted \[[@B22-cancers-11-01239]\]. This increased use of primary endocrine therapy may have been influenced by a meta-analysis, in which seven randomized controlled trials were included \[[@B25-cancers-11-01239]\]. This meta-analysis showed that, compared to those treated with primary endocrine therapy, surgery alone seemed to have no beneficial impact on the overall survival rate (HR 0.98, 95% CI 0.74--1.30). However, BC patients who underwent surgery with adjuvant endocrine therapy had a borderline significantly improved overall survival rate (HR 0.86, 95% CI 0.73--1.00) and a significantly better disease-free survival. The HR for endocrine therapy alone was 0.65 (95% CI 0.53--0.81) \[[@B25-cancers-11-01239]\].

Recent reports have advocated that primary endocrine therapy should only be considered in frail older BC patients \[[@B26-cancers-11-01239]\]. Guidelines in the Netherlands state that patients with operable tumors should be treated with surgery and not primary endocrine therapy, irrespective of age \[[@B10-cancers-11-01239]\]; also, the International Society of Geriatric Oncology (SIOG) recommends that primary endocrine therapy should only be offered to BC patients with a life expectancy of less than three years, or who are unfit for or refuse surgery \[[@B3-cancers-11-01239]\]. However, as a large proportion of older BC patients are currently being treated with primary endocrine therapy, it is not clear if this recommendation is being followed consistently. In a small retrospective study in the Netherlands, Hamakers et al. found that the reason for not carrying out surgery was not always clearly stated in medical charts. When documented, reasons were often higher age, poor overall health, patient preference, and comorbidities \[[@B21-cancers-11-01239]\]. Additionally, Sierink et al. found in a small cohort in the Netherlands that BC patients are less likely to receive surgery when they are older, have been diagnosed with more comorbidities, or have been diagnosed with a more advanced disease \[[@B27-cancers-11-01239]\]. However, other studies found that age was the most important reason for foregoing surgery in older BC patients, even when adjustments were made for comorbidities \[[@B28-cancers-11-01239],[@B29-cancers-11-01239],[@B30-cancers-11-01239]\].

Several studies found that the main factor for surgical morbidity in BC patients are comorbidities and not age \[[@B31-cancers-11-01239]\]. Breast surgery can be considered a low morbidity surgery \[[@B32-cancers-11-01239]\]. Approximately one third of BC patients develop breast and/or axillar wound infections, seromas, and hematomas after surgery, depending on the type of surgery. These surgical morbidities are often minor and treated in an outpatient setting \[[@B32-cancers-11-01239]\]. Moreover, van de Glas et al. demonstrated that relative mortality was not influenced by postoperative complications in older BC patients \[[@B33-cancers-11-01239]\].

Our study showed that the proportion of surgery in older CRC patients remains high. Many studies have shown that age should not prohibit surgery in CRC patients \[[@B16-cancers-11-01239]\]. In RC, however, the proportion of patients aged ≥75 years that received primary chemoradiation increased from 0% in 2003 to almost 20% in 2012. Recently, foregoing surgery after chemoradiation has been shown to be safe for RC patients in whom a complete clinical response is seen \[[@B34-cancers-11-01239]\].

In the present study, the proportion of older BC patients receiving adjuvant chemotherapy was lower than that of younger BC patients. In Europe, different rates of adjuvant chemotherapy in BC patients have been reported, with lower rates in the Netherlands \[[@B22-cancers-11-01239]\]. There has been conflicting evidence regarding the benefits of this treatment for older BC patients. Data from the Early Breast Cancer Trial demonstrated a decreasing benefit from adjuvant chemotherapy with age \[[@B35-cancers-11-01239],[@B36-cancers-11-01239]\], although relatively few BC patients aged 70 years or older have been included in clinical trials \[[@B5-cancers-11-01239]\]. Nevertheless, the results of this meta-analysis may have contributed to the lower use of adjuvant chemotherapy in older BC patients \[[@B35-cancers-11-01239]\]. Other recent studies suggest a possible benefit from adjuvant chemotherapy in older BC patients, especially in those with HER2-positive disease \[[@B37-cancers-11-01239],[@B38-cancers-11-01239]\]. Recently, Du et al. compared the effectiveness of adjuvant chemotherapy between older BC and CRC patients, and found that chemotherapy might be effective in BC patients up to the age of 79 years \[[@B39-cancers-11-01239]\].

Possible explanations why older BC patients receive adjuvant chemotherapy less often are frailty, poor functional status, or comorbidities. In addition, older patients are less willing to accept possible side effects associated with adjuvant chemotherapy compared with younger patients, and are concerned about negative influences of adjuvant chemotherapy. Most older BC patients receive adjuvant endocrine therapy because they are more likely to have a receptor positive disease, which tends to grow more slowly, are usually well differentiated, and respond better to endocrine therapy. However, there are side effects associated with endocrine therapy, like deep vein thrombosis or pulmonary emboli \[[@B40-cancers-11-01239]\].

The 5-year overall and relative survival improved in older CRC patients in our study. In a population-based study, Van den Broek et al. showed that 5-year relative survival had increased significantly in CC patients aged \<65 years and ≥75 years over the period from 1991 to 2005, but not in patients aged 65--74 years \[[@B41-cancers-11-01239]\]. In our study the greatest overall improvement of relative survival was seen in CRC patients aged 65--74 years (74.4% in 2003 vs. 82.3% in 2012). In the ≥75 years age group, relative survival improved significantly, but still lagged behind the survival of younger age groups. However, the difference in survival between younger and older CRC patients reported by the EUROCARE working group \[[@B1-cancers-11-01239],[@B7-cancers-11-01239]\] diminished over time in our study. This improved survival could be partly attributed to the increased use of adjuvant chemotherapy in older patients \[[@B14-cancers-11-01239]\], but also to other factors, such as improved preoperative staging and improved surgery \[[@B42-cancers-11-01239]\].

This study had some limitations. Information on patient characteristics, such as comorbidities, was not available. Furthermore, we can draw no conclusions about aspects such as quality of life, maintaining functional status, risk of recurrence, or complications, as we had no data for these outcomes. Although we adjusted the analyses for potential confounders, there may still have been some confounding by other factors. Finally, we did not have data on the causes of mortality. On the other hand, the use of data for two different tumor types means that our study does provide important insights into the differential treatment and survival trends by age. Another strength of our study is the large number of patients with BC and CRC included from the Netherlands Cancer Registry, with at least 5 years of follow-up.

4. Materials and Methods {#sec4-cancers-11-01239}
========================

4.1. Patients {#sec4dot1-cancers-11-01239}
-------------

For this population-based study, we selected all patients with primary BC and CRC stages I--II diagnosed between 2003 and 2012 from the Netherlands Cancer Registry (NCR). We only selected patients with stages I--III, as this group could potentially be treated with curative intent. Furthermore, only female BC patients were selected. The NCR records all newly diagnosed malignancies in the Netherlands after notification from the nationwide automated pathological archive (PALGA). This data is supplemented with data from the National Registry of Hospital Discharge Diagnosis. Trained registrars from the NCR routinely collect data from medical records regarding patient, tumor, and treatment characteristics in all Dutch hospitals.

Cancer stage was based on the pathological TNM classification applicable at the time of cancer diagnosis. In case of a missing pathological TNM classification, the clinical TNM classification was used instead. Data regarding the vital status of all patients was available through linkage with the municipal personal records database, with complete follow-up until 31 December 2017. Patients were divided into five groups according to age: 15--44, 45--54, 55--64, 65--74, and 75 years or older. Primary cancer treatment retrieved from the NCR included surgery, radiotherapy, endocrine therapy, immunotherapy, and (neo-)adjuvant chemotherapy.

According to the Central Committee on Research involving Human Subjects (CCMO), this type of study does not require approval from an ethics committee in the Netherlands. The Privacy Review Board of the Netherlands Cancer Registry approved this study in January 2018 (K17.351).

4.2. Statistical Analyses {#sec4dot2-cancers-11-01239}
-------------------------

All analyses were performed in IBM SPSS statistics version 22.0 (SPSS, Chicago, IL, USA) or SAS statistics version 9.4 (SAS institute, Inc., Cary, NC, USA). Statistical significance was defined as *p* ≤ 0.05.

The Cochran-Armitage trend test was used to test for differences in treatment over time. Treatments are presented as percentages per age group and period.

The Cox hazard analysis was used to calculate the overall survival. The hazard ratio (HR) was calculated according to age group and cancer stage, and adjusted for cancer stage, grade, gender, and treatment.

As cause of death is not available in the NCR, relative survival was used as an estimation of the disease-specific survival, and was calculated using the Ederer II method, i.e., as the observed overall survival of patients in the study divided by the expected overall survival in a matched group of the general population by age, sex, and year \[[@B11-cancers-11-01239]\]. The expected survival was obtained from national life tables. The relative excess risk of death (RER) was estimated using a multivariate generalized linear model with a Poisson distribution. The RER was calculated according to age and cancer type, and adjusted for cancer stage, grade, gender, and treatment. The treatment variables were added to investigate the effect of treatment on the RER.

5. Conclusions {#sec5-cancers-11-01239}
==============

In this population-based study analyzing oncological treatment patterns and relative survival of BC and CRC patients, we observed substantial differences between younger and older patients. Although the observed survival trends in BC and CRC patients suggest advances in cancer treatment, we found that the survival of older BC patients in particular was strikingly lower. Moreover, the differences in relative survival between younger and older BC patients revealed in previous studies were found to have continued to increase in recent years. Inequalities in the provision of cancer care to older BC patients need to be investigated in future cancer research. Selection criteria for specific treatments could eventually lead to individualized and optimized treatment for older cancer patients.
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cancers-11-01239-t001_Table 1

###### 

Clinical characteristics of 127,146 breast cancer (BC) and 85,629 colorectal cancer (CRC) patients, diagnosed in 2003--2012.

  Characteristics      BC        CRC             
  -------------------- --------- ------ -------- ------
   Gender                                        
  Male                 \-               45,783   53.5
  Female               127,146   100    39,846   46.5
   Age (years)                                   
  15--44               15,206    12     2077     2.4
  45--54               30,539    24     6457     7.5
  55--64               31,830    25     17,969   21
  65--74               27,095    21.3   26,839   31.3
  ≥75                  22,476    17.7   32,287   37.7
   Year of diagnosis                             
  2003                 11,669    9.2    7367     8.6
  2004                 11,848    9.3    7813     9.1
  2005                 11,845    9.3    7877     9.2
  2006                 12,264    9.6    8190     9.6
  2007                 12,725    10     8510     9.9
  2008                 12,836    10.1   8713     10.2
  2009                 12,999    10.2   8877     10.4
  2010                 13,102    10.3   9135     10.7
  2011                 13,838    10.9   9486     11.1
  2012                 14,020    11     9661     11.3
   Stage                                         
  I                    56,579    44.5   19,453   22.7
  II                   52,049    40.9   33,363   39
  III                  18,518    14.6   32,813   38.3

cancers-11-01239-t002_Table 2

###### 

Multivariate Cox hazard analysis of five-year overall survival.

  Variable                       BC                      CRC                               
  ------------------------------ ----------------------- --------- ----------------------- ---------
  Year of diagnosis (per year)   0.98 (0.97--0.98)       \<0.001   0.96 (0.96--0.97)       \<0.001
   Age                                                   \<0.001                           \<0.001
  15--44 years                   1.04 (0.97--1.11)                 **0.87 (0.76--0.98)**   
  45--54 years                   1.00 (ref)                        1.00 (ref)              
  55--64 years                   **1.35 (1.28--1.43)**             **1.25 (1.17--1.34)**   
  65--74 years                   **2.06 (1.95--2.18)**             **1.81 (1.70--1.93)**   
  ≥75 years                      **4.89 (4.60--5.18)**             **3.43 (3.22--3.65)**   
   Gender                        \-                                \<0.001                 
  Male                           \-                                1.00 (ref)              
  Female                                                           **0.82 (0.80--0.84)**   
   Stage                                                 \<0.001                           \<0.001
  I                              1.00 (ref)                        1.00 (ref)              
  II                             **1.79 (1.72--1.87)**             **1.50 (1.44--1.55)**   
  III                            **4.14 (3.96--4.32)**             **2.74 (2.64--2.84)**   
   Grade                                                 \<0.001                           \<0.001
  Well differentiated            1.00 (ref)                        1.00 (ref)              
  Moderately differentiated      **1.29 (1.22--1.35)**             1.02 (0.97--1.07)       
  Poorly differentiated and      **2.14 (2.03--2.25)**             **1.46 (1.38--1.55)**   
  undifferentiated                                                                         
  Unknown                        **1.67 (1.57--1.77)**             **1.12 (1.06--1.19)**   
  Surgery                                                \<0.001                           \<0.001
  No                             1.00 (ref)                        1.00 (ref)              
  Yes                            **0.30 (0.28--0.32)**             **0.14 (0.14--0.15)**   
  Radiotherapy                                           \<0.001                           \<0.001
  No                             1.00 (ref)                        1.00 (ref)              
  Yes                            **0.63 (0.61--0.65)**             **0.76 (0.74--0.78)**   
  Chemotherapy                                           \<0.05                            \<0.001
  No                             1.00 (ref)                        1.00 (ref)              
  Yes                            **0.95 (0.90--0.99)**             **0.64 (0.62--0.66)**   
  Hormone therapy                                        \<0.001                           
  No                             1.00 (ref)                        \-                      
  Yes                            **0.55 (0.53--0.57)**                                     

^a^ Adjusted for all variables included in the model. HR, hazard ratio. Significant (*p* \< 0.05) HR values are indicated in bold. ref, reference 95% CI, 95% Confidence Interval.
